Stroke Prevention in Atrial Fibrillation: The Role of Oral Anticoagulation

Viwe Mtwesi, Guy Amit

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Oral anticoagulation significantly reduces the risk of stroke in patients with atrial fibrillation (AF), and the decision to initiate therapy is based on assessing the patient's yearly risk of stroke. Although warfarin remains the drug of choice in patients with AF and artificial mechanical valves, the novel anticoagulation agents are becoming the drug of choice for all other patients with AF, because of their efficacy, safety, and ease of use. This article summarizes the current evidence for stroke prevention in AF, including valvular AF, subclinical AF, AF in patients with renal insufficiency, as well as stroke prevention around AF cardioversion.

Original languageEnglish
Pages (from-to)847-862
Number of pages16
JournalMedical Clinics of North America
Issue number5
StatePublished - 1 Sep 2019
Externally publishedYes


  • Anticoagulation
  • Atrial fibrillation
  • NOAC
  • Stroke prevention
  • Warfarin

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Stroke Prevention in Atrial Fibrillation: The Role of Oral Anticoagulation'. Together they form a unique fingerprint.

Cite this